Ranibizumab in retinopathy of prematurity – one‐year follow‐up of ophthalmic outcomes and two‐year follow‐up of neurodevelopmental outcomes from the CARE‐ROP study-Reference-Cited by-同舟云学术

Ranibizumab in retinopathy of prematurity – one‐year follow‐up of ophthalmic outcomes and two‐year follow‐up of neurodevelopmental outcomes from the CARE‐ROP study

Published:2021-03-19 Issue:1 Volume:100 Page:
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmologica

Author:

Stahl Andreas¹^ORCID,Bründer Marie‐Christine¹,Lagrèze Wolf A.²^ORCID,Molnár Fanni E.²,Barth Teresa³,Eter Nicole⁴,Guthoff Rainer⁵,Krohne Tim U.⁶,Pfeil Johanna M.¹^ORCID,Bühler Anima,Daniel Moritz,Felzmann Susanne,Gross Nikolai,Horn Stefanie,Müller Claudia,Reichl Sabine,Reiff Charlotte,Richter Olga,Stech Milena,Hentschel Roland,Stavropoulou Dimitra,Tautz Juliane,Bartsch Kerstin,Braunstein Jennifer,Brinken Ralf,Brinkmann Christian K,Czauderna Joanna,Dralle Wiebke,Gliem Martin,Goebel Arno,Heymer Philipp,Hofmann Martina,Holz Frank G,Kupitz David,Müller Philipp,Petrak Michael,Schmitz Eva J,Schmitz‐Valckenberg Steffen,Schröder Moritz,Steinberg Julia,Supé Julia,Kant Evelyn,Kunze Diana,Müller Andreas,Adorf Adeline,Alex Anne,Alten Florian,Clemens Christoph R,Falkenau Silvia,Friedhoff Caroline,Loos Desiree Sandra,Mihailovic Natasa,Termühlen Julia,Uhlig Constantin,Hörnig‐Franz Isabell,Rieger‐Fackeldey Esther,Tekaat Maria,Werner Claudius,Altmann Mathias,Blecha Christiane,Brandl Sabine,Helbig Horst,Hufendiek Karsten,Jägle Herbert,Konrad Julia,Kopetzky Eva,Lehmann Fabian,Oberacher‐Velten Isabel,Keller‐Wackerbauer Annette,Kittel Jochen,Segerer Hugo,Ackermann Phillip,Benga Jemina,Guthoff Tanja,Kleinert Elena,Mayatepek Ertan,Schrader Stefan,Völker Magdalena,Höhn Thomas,Lohmeier Klaus,Sabir Hemmen,Mayatepek Ertan,Brevis Francisco,Mönig Tina,Schwarz Simone,Ehmer Angela,Meltendorf Synke,Schuart Claudia,Avenarius Stefan,Böttger Ralf,Apel Christoph,Bergmann Anne,Herrmann Karsten,Ockert‐Schön Franziska,Wegener Sabine,Ehrt Oliver,Nentwich Martin,Pressler Angelika,Rudolph Günther,Genzel‐Boroviczeny Orsolya,Schmidt Susanne,Münch Hans‐Georg,Thilmany Claude,Aisenbrey Sabine,Bruckmann Anna,Dimopoulos Spyridon,Hagemann Ulrike,Inhoffen Werner,Partsch Michael,Schrader Merle,Süsskind Daniela,Völker Michael,Bialkowski Anja,Müller‐Hansen Ingo,Gerberth Andrea,Hasselbach Heike Christine,Lindemann Solveig,Purtskhvanidze Konstantine,Raffel Yvonne,Roider Johann,Gerding Heinrich,Jandeck Claudia,Smith Lois,

Affiliation:

1. Department of Ophthalmology University Medicine Greifswald Greifswald Germany

2. Eye Center Medical Center Faculty of Medicine University of Freiburg Freiburg Germany

3. Department of Ophthalmology University of Regensburg Regensburg Germany

4. Department of Ophthalmology University of Muenster Medical Center Muenster Germany

5. Department of Ophthalmology Faculty of Medicine University of Dusseldorf Dusseldorf Germany

6. Department of Ophthalmology Faculty of Medicine University Hospital Cologne University of Cologne Cologne Germany

Funder

Novartis Pharma

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.14852

Reference33 articles.

1. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity

2. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010

3. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy

4. Deutsche Ophthalmologische Gesellschaft e. V. (DOG) Retinologische Gesellschaft e. V. (RG) & Berufsverband der Augenärzte Deutschlands e. V. (BVA)(2020 May):Stellungnahme von DOG RG und BVA zur Anti‐VEGF‐Therapie der Frühgeborenenretinopathie; ROP‐Pass‐Formular zum Download. Available at:https://www.dog.org/wp‐content/uploads/2013/03/ROPPass_Version‐3_4_FORMULAR.pdf. (Accessed on 15 Mar 2021).

5. EPICE cohort: two-year neurodevelopmental outcomes after very preterm birth

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Risk Factors for Retinopathy of Prematurity Reactivation after Intravitreal Antivascular Endothelial Growth Factor Injection;The Journal of Pediatrics;2024-10

2. Novel Small Molecules with Anti-Inflammatory and Anti-Angiogenic Activity in a Mouse Model of Oxygen-Induced Retinopathy;Cells;2024-08-17

3. Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity;Frontiers in Medicine;2024-07-19

4. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial;eClinicalMedicine;2024-05

5. Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity;JAMA Network Open;2024-04-30